Milestone Pharmaceuticals Inc MIST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $0.69
- Day Range
- $0.70–0.73
- 52-Week Range
- $0.63–3.00
- Bid/Ask
- $0.73 / $0.73
- Shares Outstanding
- 124.50M
- Market Cap
- $87.65M
- Volume/Avg
- 25,524 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.87
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
Valuation
Metric | MIST |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 34.87 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MIST |
|---|---|
Quick Ratio | 7.87 |
Current Ratio | 8.13 |
Interest Coverage | −7.25 |
Quick Ratio
MIST
Profitability
Metric | MIST |
|---|---|
Return on Assets (Normalized) | −61.36% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −90.96% |
Return on Assets
MIST
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|m@GDLtb | LOCK|n&!T | $138B | |||
| Moderna Inc MRNA | LOCK|#Z%#?nh | LOCK|SR | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|fSz<^# | LOCK|D!gqx | $93B | |||
| argenx SE ADR ARGX | LOCK|r#lnv$! | LOCK|^@z | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|N$nJ&& | LOCK|vn^ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|QHSXtVl | LOCK|?&>> | $30B | |||
| Incyte Corp INCY | LOCK|!DvD!G> | LOCK|^T% | $24B | |||
| BioNTech SE ADR BNTX | LOCK|K!?W?# | LOCK|F?% | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|M#htB%j | LOCK|H@L% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|!>QzVr | LOCK|@Dk | $15B |
United States